NCT00000742View on ClinicalTrials.gov

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1993

Conditions
HIV Infections
Interventions
DRUG

Atevirdine mesylate

DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (5)

14642

Univ. of Rochester ACTG CRS, Rochester

90033

USC CRS, Los Angeles

Unknown

Univ. of Miami AIDS CRS, Miami

Washington U CRS, St Louis

The Ohio State Univ. AIDS CRS, Columbus

Sponsors

Collaborators (2)

Upjohn
Glaxo Wellcome
All Listed Sponsors
collaborator

Upjohn

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH